These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 16571091

  • 1. Incidence of postradioiodine immunogenic hyperthyroidism/Graves' disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid disease.
    Schmidt M, Gorbauch E, Dietlein M, Faust M, Stützer H, Eschner W, Theissen P, Schicha H.
    Thyroid; 2006 Mar; 16(3):281-8. PubMed ID: 16571091
    [Abstract] [Full Text] [Related]

  • 2. Thyrotropin receptor antibodies and Graves' disease, a side-effect of 131I treatment in patients with nontoxic goiter.
    Nygaard B, Knudsen JH, Hegedüs L, Scient AV, Hansen JE.
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2926-30. PubMed ID: 9284721
    [Abstract] [Full Text] [Related]

  • 3. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.
    Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Tørring O.
    Eur J Endocrinol; 2008 Jan; 158(1):69-75. PubMed ID: 18166819
    [Abstract] [Full Text] [Related]

  • 4. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.
    Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T, Dokic D, Latrofa F, Mammoli C, Lippi F, Ceccarelli C, Pinchera A.
    J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. TSH-receptor autoantibodies - differentiation of hyperthyroidism between Graves' disease and toxic multinodular goitre.
    Wallaschofski H, Kuwert T, Lohmann T.
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):171-4. PubMed ID: 15127319
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
    Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M, Miyamoto T, Arai M, Nagasawa T.
    N Engl J Med; 1991 Apr 04; 324(14):947-53. PubMed ID: 1900575
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Appearance of anti TSH-receptor antibodies and clinical Graves' disease after radioiodine therapy for hyperfunctioning thyroid adenoma.
    Regalbuto C, Salamone S, Scollo C, Vigneri R, Pezzino V.
    J Endocrinol Invest; 1999 Feb 04; 22(2):147-50. PubMed ID: 10195384
    [Abstract] [Full Text] [Related]

  • 11. Enhanced thyroid iodine metabolism in patients with triiodothyronine-predominant Graves' disease.
    Takamatsu J, Hosoya T, Naito N, Yoshimura H, Kohno Y, Tarutani O, Kuma K, Sakane S, Takeda K, Mozai T.
    J Clin Endocrinol Metab; 1988 Jan 04; 66(1):147-52. PubMed ID: 3335601
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Incidence of radiation-induced Graves' disease in patients treated with radioiodine for thyroid autonomy before and after introduction of a high-sensitivity TSH receptor antibody assay.
    Dunkelmann S, Wolf R, Koch A, Kittner C, Groth P, Schuemichen C.
    Eur J Nucl Med Mol Imaging; 2004 Oct 04; 31(10):1428-34. PubMed ID: 15221291
    [Abstract] [Full Text] [Related]

  • 15. Incidence of radioiodine induced Graves' disease in patients with multinodular toxic goiter.
    Meller J, Siefker U, Hamann A, Hüfner M.
    Exp Clin Endocrinol Diabetes; 2006 May 04; 114(5):235-9. PubMed ID: 16804797
    [Abstract] [Full Text] [Related]

  • 16. Postradioiodine Graves' management: The PRAGMA study.
    Perros P, Basu A, Boelaert K, Dayan C, Vaidya B, Williams GR, Lazarus JH, Hickey J, Drake WM, Crown A, Orme SM, Johnson A, Ray DW, Leese GP, Jones TH, Abraham P, Grossman A, Rees A, Razvi S, Gibb FW, Moran C, Madathil A, Žarković MP, Plummer Z, Jarvis S, Falinska A, Velusamy A, Sanderson V, Pariani N, Atkin SL, Syed AA, Sathyapalan T, Nag S, Gilbert J, Gleeson H, Levy MJ, Johnston C, Sturrock N, Bennett S, Mishra B, Malik I, Karavitaki N.
    Clin Endocrinol (Oxf); 2022 Nov 04; 97(5):664-675. PubMed ID: 35274331
    [Abstract] [Full Text] [Related]

  • 17. The tale of radioiodine and Graves' orbitopathy.
    Ponto KA, Zang S, Kahaly GJ.
    Thyroid; 2010 Jul 04; 20(7):785-93. PubMed ID: 20578895
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B, Hoermann R, Roggenbuck U, Hahn S, Mann K, Janssen OE, Basedow Study Group.
    Thyroid; 2005 Sep 04; 15(9):1047-54. PubMed ID: 16187913
    [Abstract] [Full Text] [Related]

  • 20. Induction of stimulating thyrotropin receptor antibodies after radioiodine therapy for toxic multinodular goitre and Graves' disease measured with a novel bioassay.
    Hovens GC, Heemstra KA, Buiting AM, Stokkel MP, Karperien M, Ballieux BE, Pereira AM, Romijn JA, Smit JW.
    Nucl Med Commun; 2007 Feb 04; 28(2):123-7. PubMed ID: 17198353
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.